PEG-MGF
Pegylated Mechano Growth Factor (PEGylated IGF-1Ec E-domain peptide). Synonyms: PEG-MGF, Pegylated MGF, PEGylated Mechano-Growth Factor, MECHA-FACTO (brand name, DenikPharm).
FDA has identified this as a Category 2 bulk drug substance with significant safety risks for compounding. No human exposure data exists.
A modified form of a natural muscle-repair signal the body produces after exercise or injury, chemically altered to last longer in the body. It has shown the ability to activate muscle repair cells in animal studies, but no human clinical trials exist.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
CRITICAL CAVEAT: All side effect frequency estimates for PEG-MGF are from vendor/product summaries, community/anecdotal reports, and extrapolation from related PEGylated compounds -- NOT from controlled human clinical trials, which do not exist for PEG-MGF. No reproducible peer-reviewed body of evidence documents frequent or clearly attributable serious adverse events (SAEs) for PEG-MGF in humans. FDA FAERS and EMA EudraVigilance public databases returned no identifiable spontaneous-report signals for PEG-MGF as of March 2026. Class-level immunogenicity risks are salient: anti-PEG antibodies (IgM/IgG) can be pre-existing or treatment-induced, may cause accelerated blood clearance (ABC) and loss of efficacy, and can predispose to hypersensitivity or CARPA reactions (PMC12388889). Theoretical long-term risks include the promotion of undetected tumor growth due to the potent proliferative mechanism. Long-term human safety data are effectively absent. Unregulated sourcing and variable product purity in research/consumer markets create ongoing safety concerns.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-11]